Skip to content

Effectiveness of Bi-Sai-Tong solution for moderate to severe allergic rhinitis: a randomized controlled study

A multicenter, randomized controlled clinical trial of Bi-Sai-Tong solution for moderate to severe allergic rhinitis

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR1900025162
Enrollment
Unknown
Registered
2019-08-15
Start date
2019-08-01
Completion date
Unknown
Last updated
2019-08-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

allergic rhinitis

Interventions

Sponsors

Guangdong Provincial Hospital of Chinese Medicine
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 65 Years

Inclusion criteria

Inclusion criteria: 1. Aged 18 to 65 years, both men and women; 2. Accorded with allergic rhinitis diagnostic criteria; 3. moderate-severe allergic rhinitis; 4. RQLQ scores >= 42 points 5. Patients signed informed consent.

Exclusion criteria

Exclusion criteria: 1. Patients with moderate-severe deviation of nasal septum, sinusitis, rhinopolyp, nasopharynx cancer and other severe nasal diseases; 2. Patients with serious heart,liver,lung,kidney and blood system diseases; 3. Patients with unstable asthma control; 4. Psychiatric patients; 5. Those who are in on-going trial or ready to attend other clinical trials; 6. Allergic to the traditional Chinese medicine ingredients contained in the treatment drug; 7. Women during pregnant stage and breast-feed stage.

Design outcomes

Primary

MeasureTime frame
Rhinoconjunctivitis Quality of Life Questionnaire, RQLQ;

Secondary

MeasureTime frame
Questionnaire of nose and eyes;Frequency and dosage of medicine;Rhinitis exacerbation days;Inhaled allergen test;ECP;Visual Analogue Score, VAS;

Countries

China

Contacts

Public ContactChen Yuanbin

Guangdong Provincial Hospital of Chinese Medicine

chenyuanbin110@163.com+86 15920174645

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026